Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

…, M Korenaga, K Hino, S Hige, Y Ito, E Mita… - Nature …, 2009 - nature.com
The recommended treatment for patients with chronic hepatitis C, pegylated interferon-α (PEG-IFN-α)
plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all …

[HTML][HTML] Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean

…, E Tanaka, M Honda, S Kaneko, E Orito, Y Itoh, E Mita… - PloS one, 2012 - journals.plos.org
Hepatitis B virus (HBV) infection can lead to serious liver diseases, including liver cirrhosis (LC)
and hepatocellular carcinoma (HCC); however, about 85–90% of infected individuals …

[HTML][HTML] Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

…, H Shindou, M Miyazaki, Y Imai, S Tanaka, E Mita… - Hepatology, 2023 - journals.lww.com
… Murai, Hiroki 1 ; Kodama, Takahiro 1 ; Maesaka, Kazuki 1 ; Tange, Shoichiro 2 ; Motooka,
Daisuke 3 ; Suzuki, Yutaka 4 ; Shigematsu, Yasuyuki 5 ; Inamura, Kentaro 5 ; Mise, Yoshihiro 6 ; …

[HTML][HTML] Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 …

…, T Kanda, M Sakamoto, A Tamori, E Mita… - Journal of …, 2019 - Springer
Background In Japan, hepatitis C virus (HCV)-infected patients with decompensated
cirrhosis currently have no treatment options. In this Phase 3 study, we evaluated sofosbuvir–…

[PDF][PDF] Risk factors for long‐term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults

…, T Ichida, H Toyoda, M Yoneda, E Mita… - …, 2014 - Wiley Online Library
The proportion of patients who progress to chronicity following acute hepatitis B (AHB)
varies widely worldwide. Moreover, the association between viral persistence after AHB and …

[HTML][HTML] Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy

…, Y Imai, K Ohkawa, M Miyazaki, S Tanaka, E Mita… - Cancers, 2022 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide.
Due to its high recurrence rate, many HCC patients progress to an advanced stage and …

Role of Fas ligand in apoptosis induced by hepatitis C virus infection

E Mita, N Hayashi, S Iio, T Takehara, T Hijioka… - Biochemical and …, 1994 - Elsevier
To investigate the role that Fas ligand plays in the apoptosis of hepatocytes induced by
hepatitis C virus infection, we isolated a cDNA clone for human Fas ligand and examined the …

Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy

…, A Yamada, M Oshita, H Hagiwara, E Mita… - Clinical …, 2014 - Elsevier
Background & Aims In patients with chronic hepatitis C virus (HCV) infection, lack of sustained
virologic response (SVR) 24 weeks after the end of interferon therapy is a significant risk …

[HTML][HTML] Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy

…, T Nakabori, K Ohkawa, M Miyazaki, S Tanaka, E Mita… - Cancers, 2022 - mdpi.com
Simple Summary Atezolizumab/bevacizumab (Atezo/Bev) combination immunotherapy has
become a front-line therapy for unresectable hepatocellular carcinoma (u-HCC), but some …

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

H Hagiwara, N Hayashi, E Mita, T Takehara… - Gastroenterology, 1993 - Elsevier
Background: Interferon alfa is effective for controlling disease activity in chronic hepatitis C.
However, many responders suffer relapse after cessation of therapy. In the present study, the …